Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Session Type:

Availability:

I WANT A NEW DRUG

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 7 of 7
THEMED DISCUSSION LEADER
Karl Salzwedel
National Institutes of Health, Bethesda , MD, USA
from CROI 2017 on February 16, 2017 1:30 PM-2:30 PM
NOVEL HIV PI WITH HIGH RESISTANCE BARRIER AND POTENTIAL FOR UNBOOSTED QD ORAL DOSING
John O Link
Gilead Sciences, Foster City, CA, USA
from CROI 2017 on February 16, 2017 1:30 PM-2:30 PM
NOVEL NON-CATALYTIC SITE INTEGRASE INHIBITOR WITH IMPROVED RESISTANCE PROFILE
Michael Lloyd Mitchell
Gilead Sciences, Foster City, CA, USA
from CROI 2017 on February 16, 2017 1:30 PM-2:30 PM
MK-8591 CONCENTRATIONS AT SITES OF HIV TRANSMISSION AND REPLICATION
Jay Grobler
Merck & Co, West Point, PA, USA
from CROI 2017 on February 16, 2017 1:30 PM-2:30 PM
GS-9131 IS A NOVEL NRTI WITH ACTIVITY AGAINST NRTI-RESISTANT HIV-1
Kirsten Lofgren White
Gilead, Foster City, CA, USA
from CROI 2017 on February 16, 2017 1:30 PM-2:30 PM
PRO140 Single-Agent Maintenance Therapy for HIV-1 Infection: A 2-Year Update
Kush Dhody
Amarex Clinical Research, LLC, Germantown, MD, USA
from CROI 2017 on February 16, 2017 1:30 PM-2:30 PM
QUESTIONS AND ANSWERS
from CROI 2017 on February 16, 2017 1:30 PM-2:30 PM
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 7 of 7